At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of CCI-779 in Combination With Bevacizumab in Stage III or IV Melanoma
In Brief
A Phase 2 clinical trial evaluating Bevacizumab, Laboratory Biomarker Analysis, and 2 other interventions for Recurrent Melanoma and 3 related conditions. Completed, enrolled 17 participants across 2 sites.
Detailed Summary
This phase II trial is studying how well giving temsirolimus together with bevacizumab works in treating patients with stage III or stage IV malignant melanoma. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for their growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of malignant melanoma by blocking blood flow to the tumor. Giving temsirolimus together with bevacizumab may kill more tumor cells.
Study Details
Timeline
Interventions
Given IV
Correlative studies
Given IV
Undergo tumor resection